Gland Pharma Limited has informed the Exchange regarding a press release dated November 03, 2025, titled "Press release on Q2FY26 Financial Results".
GLAND · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Gland Pharma reported consolidated revenue of ₹14,869 crore in Q2 FY26, up 6% year-on-year, with PAT rising 12% to ₹1,837 crore. For the first half of FY26, revenue grew 7% to ₹29,925 crore while PAT jumped 30% to ₹3,992 crore. Adjusted EBITDA margin expanded by 150 basis points year-on-year for the quarter and 370 basis points for the half year, reaching 23% in H1 FY26. USA revenue grew 10%, Europe 16%, and the European subsidiary Cenexi saw a 21% revenue increase although it remained in negative EBITDA due to a planned shutdown. The company launched 7 new molecules in the USA, filed 6 ANDAs, and is expanding GLP-1/pen/cartridge capacity from 40 million to 140 million units.
Strong half-yearly performance with 30% PAT growth and meaningful margin expansion signals healthy operating leverage and execution on cost improvements. Sequential decline in quarterly numbers (revenue -1%, PAT -15% QoQ) and continued losses at Cenexi are minor concerns, but management's outlook remains positive with new launches and capacity expansion expected to drive H2 momentum.